Sangamo Therapeutics
SGMO
#8727
Rank
โ‚ฌ0.14 B
Marketcap
0,43ย โ‚ฌ
Share price
-6.45%
Change (1 day)
-77.61%
Change (1 year)

Revenue for Sangamo Therapeutics (SGMO)

Revenue in 2025 (TTM): โ‚ฌ29.23 Million

According to Sangamo Therapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ28.23 Million. In 2024 the company made a revenue of โ‚ฌ55.54 Million a decrease over the revenue in the year 2023 that were of โ‚ฌ0.15 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Sangamo Therapeutics from 2000 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚ฌ29.23 M-47.37%
2024 โ‚ฌ55.54 M-65.16%
2023 โ‚ฌ0.15 B53.64%
2022 โ‚ฌ0.10 B6.15%
2021 โ‚ฌ97.74 M1.72%
2020 โ‚ฌ96.09 M5.09%
2019 โ‚ฌ91.43 M23.86%
2018 โ‚ฌ73.82 M142.23%
2017 โ‚ฌ30.47 M65.33%
2016 โ‚ฌ18.43 M-49.03%
2015 โ‚ฌ36.16 M-4.12%
2014 โ‚ฌ37.71 M115.83%
2013 โ‚ฌ17.47 M6.74%
2012 โ‚ฌ16.37 M106.03%
2011 โ‚ฌ7.94 M-49.2%
2010 โ‚ฌ15.64 M1%
2009 โ‚ฌ15.48 M33.75%
2008 โ‚ฌ11.57 M85.81%
2007 โ‚ฌ6.23 M4.27%
2006 โ‚ฌ5.97 M185.09%
2005 โ‚ฌ2.09 M116.22%
2004 โ‚ฌ0.96 M-52.68%
2003 โ‚ฌ2.04 M-50.69%
2002 โ‚ฌ4.15 M-24.89%
2001 โ‚ฌ5.53 M51.79%
2000 โ‚ฌ3.64 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Gilead Sciences
GILD
โ‚ฌ24.98 B 88,374.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ2.75 B 9,664.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚ฌ30.89 B 109,317.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
โ‚ฌ8.64 B 30,518.71%๐Ÿ‡บ๐Ÿ‡ธ USA
Dow
DOW
โ‚ฌ35.14 B 124,350.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚ฌ79.14 B 280,201.14%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ2.65 B 9,311.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
โ‚ฌ55.17 B 195,291.63%๐Ÿ‡บ๐Ÿ‡ธ USA